Biotech Sector Sees Mixed Clinical Trial Results, Key Drug Data Drives Stock Swings

Candel Therapeutics, Inc. (Nasdaq: CADL) announced clinical and biomarker data from its phase 3 PrTK03 and phase 2 PrTK05 trials evaluating aglatimagene besadenovec in patients with intermediate-risk localized prostate cancer, according to a company press release.

In the PrTK03 phase 3 trial, 635 patients with intermediate-risk disease treated with aglatimagene plus external beam radiation therapy (EBRT) showed a 41% reduction in the risk of prostate cancer recurrence or prostate cancer-specifi

Investing.com -- Sagimet Biosciences Inc Series A (NASDAQ: SGMT) shares rose over 12% in premarket trading Wednesday following positive 52-week results from its license partner Ascletis' Phase 3 open-label extension trial of denifanstat for moderate to severe acne.

The trial showed denifanstat achieved a 57% treatment success rate, with a 72% reduction in total lesions and 77% reduction in inflammatory lesions after 52 weeks of treatment. The drug was generally well-tolerated, with no adverse e

Theriva Biologics (NYSE American: TOVX) announced that results from its VIRAGE Phase 2b clinical trial of VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic cancer patients were published in Nature Medicine, according to a company statement.

The trial enrolled 112 patients across 14 sites in the U.S. and Spain. Patients in the VCN-01 treatment arm received intravenous VCN-01 seven days prior to the first and fourth cycles of standard-of-care gemcitabine/nab-paclitaxel chemotherapy. The

Investing.com -- Rafael Holdings Inc Class B (NYSE: RFL) shares fell 25% in premarket trading Wednesday after the company's Phase 3 trial of Trappsol Cyclo for Niemann-Pick Disease Type C failed to meet its primary endpoint.

The TransportNPC study, which enrolled 94 patients, showed Trappsol Cyclo did not achieve statistical significance on the primary endpoint of change in the 4-domain NPC Clinical Severity Scale at Week 96. The drug demonstrated a directionally favorable treatment effect vers

Merck (MRK) announced results from a Phase 2b trial of tulisokibart, an investigational monoclonal antibody, in patients with moderate to severe hidradenitis suppurativa (HS), a chronic inflammatory skin disease. The data were presented at the European Academy of Dermatology and Venereology 2026 Congress.

The trial, designated MK-7240-012, met its primary endpoint of HiSCR50 — a 50% reduction in abscesses and inflammatory nodules — at week 16. In the high-dose group (480 mg every two weeks), 72

INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY) announced today that its drug Ebglyss met primary and secondary endpoints in a Phase 3b clinical trial for patients with moderate-to-severe hand and foot atopic dermatitis, according to a press release statement.

The ADtouch study evaluated 221 adults and adolescents who received either Ebglyss or placebo every two weeks for 16 weeks. At Week 16, 53% of patients treated with Ebglyss achieved clear or almost clear skin on hands and feet, compared t